Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.

REACH

ß-Cyclodextrin, acetyl

EC number: 418-780-1 | CAS number: -

Life Cycle description
Uses advised against

Toxicological information

Endpoint summary

Administrative data

Description of key information

Key value for chemical safety assessment

Skin sensitisation

Link to relevant study records

Reference

Endpoint:

skin sensitisation: in vivo (non-LLNA)

Type of information:

experimental study

Adequacy of study:

key study

Study period:

1997

Reliability:

1 (reliable without restriction)

Rationale for reliability incl. deficiencies:

other: OECD Guideline Study

Qualifier:

according to guideline

Guideline:

OECD Guideline 406 (Skin Sensitisation)

GLP compliance:

yes

Type of study:

guinea pig maximisation test

Justification for non-LLNA method:

Test performed in 1997, LLNA had not been available yet.

Species:

guinea pig

Strain:

Pirbright-Hartley

Sex:

female

Details on test animals and environmental conditions:

Pirbright-White guinea pig / female
HsdPoc:DH
HARLAN WINKELMANN
Gartenstr. 27
D-33178 Borchen
SPF breeding colony
Body weight at start of study
mean = 368 g (= 100 %)
min = 335 g (- 9.0 %)
max = 403 g (+ 9.5 %)
n = 15
fur marking with KMn04 and cage numbering

Route:

intradermal and epicutaneous

Vehicle:

other: Oleum sesami DAB 10

Concentration / amount:

Concentration of test material and vehicle used at induction:
intradermal: 2 % Oleum sesami DAB 10
dermal: 25 % in Oleum sesami DAB 10
Concentration of test material and vehicle used for each challenge:
25 % in Oleum sesami DAB 10

Route:

epicutaneous, occlusive

Vehicle:

other: Oleum sesami DAB 10

Concentration / amount:

No. of animals per dose:

Number of animals in test group: 10
Number of animals in negative control group: 5

Details on study design:

Treatment group
1.) 50 % Freund's Complete Adjuvant emulsion
Original Freund's Complete Adjuvant (Sigma Chemical Company) was mixed
immediately before use with an equal volume of deionized water.
2.) 2 % Beta W 7 A 1.0 in Sesame oil (Oleum sesami DAB 10)
3.) 2 % Beta W 7 A 1.0 in a 50 % Freund's Complete Adjuvant emulsion
For the intradermal injections of the test substance in 50 % Freund's adjuvant, Beta W
7 A 1.0 was dissolved in Freund's Original Adjuvant and then mixed with an equal
volume of deionized water [percentages w/v].
For the dermal treatments, Beta W 7 A 1.0 was suspended in Sesame oil
[percentages w/v].

An amount of 0.5 ml of the test substance preparation (treatment group)
or the vehicle (control group) was administered to a 2 x 4 cm cellulose
patch, This patch covered the area where the intradermal injection had
been placed. The administration area was then kept for 48 hours under
an occlusive bandage with an impermeable film and an elastic bandage.
Treatment group 25.0 % test substance in sesame oil
Control group sesame oil
Occlusive bandage removed, irritant effects recorded.
No treatment of control or treatment group.
Test animals kept under observation.

Challenge controls:

Control group
1.) 50 % Freund's Complete Adjuvant emulsion
Original Freund's Complete Adjuvant (Sigma Chemical Company) was mixed
immediately before use with an equal volume of deionized water.
2.) Sesame oil (Oleum sesami DAB 10)
3.) 50 % Freund's Complete Adjuvant emulsion mixed with an equal volume of the
vehicle

Positive control substance(s):

yes

Remarks:

Benzocain

Positive control results:

The validity of the test system is confirmed by the periodically conducted positive
control test using benzocain for the maximization test (report number 97.0326, dated
June 02, 1997; Hoechst Marion Roussel, Preclinical Development Germany, Drug
Safety).

Reading:

1st reading

Hours after challenge:

Group:

test chemical

Dose level:

25 %

No. with + reactions:

Total no. in group:

Remarks on result:

other: Reading: 1st reading. . Hours after challenge: 24.0. Group: test group. Dose level: 25 %. No with. + reactions: 0.0. Total no. in groups: 10.0.

Reading:

2nd reading

Hours after challenge:

Group:

test chemical

Dose level:

25 %

No. with + reactions:

Total no. in group:

Remarks on result:

other: Reading: 2nd reading. . Hours after challenge: 48.0. Group: test group. Dose level: 25 %. No with. + reactions: 0.0. Total no. in groups: 10.0.

Intradermal induction treatment

Two intradermal injections per animal of the following preparations. The

injection sites (site 1, 2 and 3) were all within a dorsal area of 2 x 4 cm

(see prior page). The injection sites were left uncovered.

Dermal induction treatment

An amount of 0.5 ml of the test substance preparation (treatment group)

or the vehicle (control group) was administered to a 2 x 4 cm cellulose

patch, This patch covered the area where the intradermal injection had

been placed. The administration area was then kept for 48 hours under

an occlusive bandage with an impermeable film and an elastic bandage.

Dermal challenge treatment

One area of approx. 5 x 5 cm on the left flank was shaved mechanically.

An amount of 0.5 ml of the test substance preparation was administered

to a 2 x 2 cm cellulose patch. The administration area was then kept for

24 hours under an occlusive bandage with an impermeable film and an

elastic bandage.

Interpretation of results:

GHS criteria not met

Remarks:

Migrated information

Conclusions:

Based on the results of an OECD 406 study (GM Beta W 7 A 1.0 showed no evidence for sensitizing properties.

Executive summary:

Under the conditions of the present study, none of ten animals of the treatment group

showed a positive skin response after the challenge procedure.

Thus, the percentage of animals reacting positive is below the threshold of 30 %.

Based on the results of this study Beta W 7 A 1.0 showed no evidence for sensitizing

properties.

Endpoint conclusion

Endpoint conclusion:

no adverse effect observed (not sensitising)

Additional information:

Under the conditions of the present study, none of ten animals of the treatment group

showed a positive skin response after the challenge procedure.

Thus, the percentage of animals reacting positive is below the threshold of 30 %.

Based on the results of this study Beta W 7 A 1.0 showed no evidence for sensitizing

properties.

Migrated from Short description of key information:
Based on the results of an OECD 406 study (GM Beta W 7 A 1.0 showed no evidence for sensitizing properties.

Justification for selection of skin sensitisation endpoint:
OECD Guideline Study

Respiratory sensitisation

Endpoint conclusion

Endpoint conclusion:: no study available

Justification for classification or non-classification

Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.